These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 6135735)
1. The use of sulfasalazine in the treatment of inflammatory bowel disease. Spector R J Iowa Med Soc; 1983 Jun; 73(6):230-4. PubMed ID: 6135735 [No Abstract] [Full Text] [Related]
2. Sulfasalazine therapy in inflammatory bowel disease. Das KM Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989 [TBL] [Abstract][Full Text] [Related]
3. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Faintuch J; Mott CB; Machado MC Int Surg; 1985; 70(3):271-2. PubMed ID: 2872181 [TBL] [Abstract][Full Text] [Related]
4. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. Korelitz BI; Present DH; Rubin PH; Fochios SE J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067 [TBL] [Abstract][Full Text] [Related]
5. Sulphasalazine in inflammatory bowel disease: recent advances. Cooper BT N Z Med J; 1986 Oct; 99(811):757-9. PubMed ID: 2877428 [No Abstract] [Full Text] [Related]
6. Inflammatory bowel disease. Part II. Hansen R Proc Annu Meet Med Sect Am Counc Life Insur; 1978; ():41-9. PubMed ID: 39296 [No Abstract] [Full Text] [Related]
7. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid]. Malchow H Internist (Berl); 1987 Jan; 28(1):14-20. PubMed ID: 2883152 [No Abstract] [Full Text] [Related]
8. Pharmacotherapy of inflammatory bowel disease. Gardner RC J Maine Med Assoc; 1976 Jul; 67(7):206-14. PubMed ID: 9461 [No Abstract] [Full Text] [Related]
9. Proceedings: Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Lendrum R; Walker JG; West B; Hill MJ Gut; 1974 Apr; 15(4):344. PubMed ID: 4151868 [No Abstract] [Full Text] [Related]
10. [Salazosulfapyridine: old and new therapy concepts in inflammatory bowel diseases]. Allgayer H; Kruis W Dtsch Med Wochenschr; 1985 Nov; 110(47):1827-9. PubMed ID: 2866083 [No Abstract] [Full Text] [Related]
11. [40 years of salazosulfapyridine. Is end in sight?]. van Hees PA; van Tongeren JH Ned Tijdschr Geneeskd; 1982 Oct; 126(44):2014-8. PubMed ID: 6129576 [No Abstract] [Full Text] [Related]
12. [Drug treatment of chronic inflammatory diseases of the intestine]. Modigliani R Schweiz Med Wochenschr; 1988 May; 118(20):737. PubMed ID: 2898809 [No Abstract] [Full Text] [Related]
13. [New developments and trends in the drug therapy of chronic inflammatory bowel diseases]. Ewe K Verh Dtsch Ges Inn Med; 1988; 94():178-84. PubMed ID: 2905098 [No Abstract] [Full Text] [Related]
14. [Exacerbation of ulcerative colitis and Crohn disease as a phenomenon inherent in the disease]. Habs M; Schifmann R Dtsch Med Wochenschr; 1986 Jul; 111(28-29):1131. PubMed ID: 2874004 [No Abstract] [Full Text] [Related]
15. II. Medical treatment of inflammatory bowel disease. Gray GM Calif Med; 1973 Nov; 119(5):21-4. PubMed ID: 4148269 [No Abstract] [Full Text] [Related]
16. [Immunomodulation treatment of inflammatory bowel disease]. Stave R Tidsskr Nor Laegeforen; 1984 Jan; 104(3):153-4. PubMed ID: 6142543 [No Abstract] [Full Text] [Related]